Using a 5% immunoreactivity cutoff, the DSG3 positivity was 18% for esophageal adenocarcinoma, 0% for small-cell lung carcinoma, and 0% for large B-cell lymphoma. This evidence concerns the gene DSG3 and esophageal adenocarcinoma.